Citi Group Entities Exit Substantial Holder Position in Australian Clinical Labs

Australian Clinical Labs Ltd ( (AU:ACL) ) has provided an announcement.

Citigroup Global Markets Australia Pty Limited and related Citi group entities have ceased to be substantial holders in Australian Clinical Labs, after reducing their relevant interest in the company’s ordinary fully paid shares. The change stems from decreased holdings under securities lending arrangements managed through Citibank, N.A. Sydney Branch and Citigroup Global Markets Limited, signaling a notable shift in a key institutional holder’s position in ACL’s share register and potentially altering the company’s institutional ownership profile.

The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.

More about Australian Clinical Labs Ltd

Australian Clinical Labs Ltd operates in the pathology and medical diagnostics industry, providing laboratory testing services across Australia. The company focuses on routine and specialist pathology services to healthcare providers and patients, competing in a regulated market where share registers and substantial holdings are closely monitored by investors and regulators.

Average Trading Volume: 674,838

Technical Sentiment Signal: Sell

Current Market Cap: A$413.3M

See more insights into ACL stock on TipRanks’ Stock Analysis page.